Inferre Consulting GmbH

🔔 Pharmaceutical Sales Growth in 2025 – Top 3 Drivers of the Year! https://lnkd.in/dP9gvVrn   🔜 In 2025, #pharmaceutical #sales are set to return to their normal growth patterns, excluding the COVID-affected years. Analysts predict a remarkable $72bn increase over 2024, marking the largest annual growth in a decade outside of the 2021 spike.   ➡️ This #newsletter, authored by Avisek Ghose, is focusing on the top three growth areas — solid #tumors, metabolic disorders, and #diabetes #treatments, which are expected to drive significant #market expansion, contributing a combined $34.5bn to the overall $54bn growth from the top 10 #therapeutic areas.   Let’s have a look at the statistics of the prediction! ⬆️ Read here: https://lnkd.in/dP9gvVrn 🌐 Subscribe to our newsletter for regular updates: https://lnkd.in/dhn-k5KZ   #pharmamarket #marketanalysis #pharmasales #markettrend

➡️ Recent News on Health Economics and Outcomes Research (#HEOR)    ☑️ GPT-3’s Diagnostic Accuracy A study in The Lancet Digital Health shows GPT-3 correctly diagnosed cases in its top 3 predictions 88% of the time, outperforming lay individuals (54%) and closely trailing physicians (96%). However, it deprioritized truly emergent cases in 7 instances.   ☑️ Healthcare Systems & HEOR As highlighted in Value & Outcomes Spotlight, #healthcare systems are striving to balance advanced treatments with affordability and accessibility, aiming to provide optimal care at reasonable costs.   ☑️ Medicaid & Data Science Health Affairs Forefront critiques value-based care models in Medicaid as “value veneers” due to data quality issues and poor integration of #clinical and social risk factors, limiting their effectiveness.   ☑️ National Health Expenditure Projections Health Affairs reports a 7.5% growth in national health expenditures in 2023 post-COVID-19 emergency. From 2027-2032, healthcare spending is expected to outpace economic growth due to price inflation and increased service use.   ☑️ ISPOR’s Strategic Plan 2030 ISPOR’s new plan envisions a future where healthcare is accessible, effective, efficient, and affordable for all.   ☑️ Health Literacy & Equity Health Affairs emphasizes the need for strategies to improve health literacy and digital health literacy to advance health equity.   ☑️ Medicare Savings Program Policy experts suggest aligning MSP eligibility with the Medicare Part D Low-Income Subsidy program to increase enrollment and improve care for dual-eligible individuals.   ☑️ Remote Symptom Monitoring in Oncology A study in The Lancet Regional Health #Europe shows that remote #patient monitoring in 33 #cancer centers led to significant symptom improvement in 94.6% of cases within 2 weeks.   ☑️ NICE & Drug Pricing NICE and #NHS England express disappointment over high pricing for Enhertu, preventing its recommendation for advanced HER2-low breast cancer.   ☑️ Cost-Saving Clot-Busting Drug NICE recommends Tenecteplase, a cost-effective alternative for treating acute ischemic stroke, potentially saving the NHS millions.   ☑️ Pandemic Preparedness CEPI and WHO call for broader research on pathogen families to prepare for future pandemics, using “prototype pathogens” as guides.   ☑️ mRNA Vaccine Development Sinergium Biotech, supported by WHO and the Medicines Patent Pool, is advancing mRNA vaccines for avian influenza in low- and middle-income countries.   ➕ Source: ISPOR—The Professional Society for Health Economics and Outcomes Research news desk. 📌 Author: Avisek Ghose   #healthcare #AI #medicaid #healthequity #pandemicpreparedness #mRNA #ISPOR #NICE #GPT3 #digitalhealth

Top-5 Pharma News and Market Trend in 2024 - #newsletter from Avisek Ghose

The #pharmaceutical industry’s outlook for 2024 by Robert F. Siegmund, PhD MBA is shaped by several key themes like Health System Reforms, Demographic Shifts, Changing #Patient Experiences and Expectations. #biopharma #insights #analytics

🔜  (Are you) Entering Switzerland with Medicinal Products? 🔔 Different rules for different #pharma #products in 🇨🇭 🌐 https://lnkd.in/dEV7rzUM ☑️ Remember to follow the guidelines from Swissmedic to ensure a smooth entry with your medicinal products! #pharmaregulation #swisspharma #swissmedic

Hello LinkedIn community! 👋 👉 I am currently looking for a skilled #webdesigner to enhance the graphical representation and content of my #website (https://lnkd.in/gA7R5EY6). This is a #WordPress based #website and will be re-launched with better features for visually appealing.   Overview: ☑️ Improving the website’s aesthetics, content and usability. ☑️ Including plugins (#SEO etc.) to improve visitor experience and traffic. ☑️ Creating stunning visuals, infographics, and data visualizations.   🤝 Could be a good learning experience for upcoming web designers.   ➡️ Please send a direct #message to Avisek Ghose if you are ready to take this small #project.   ➡️ Feel free to share this post or tag talented designers you know.   #webdesign #UX #webdesigners

Insightful #newsletter from Avisek Ghose

👉 Free up your time for other responsibilities;   🔜 As an experienced associate to manage #Pharma and #MedTech market research and market access projects, I am extending my service as “job-shadowing” and available for the next couple of months, with a maximum commitment of 0.35 FTE.   ➡️ My top-5 relevant contributions; ✔️ Secondary Market Research: document/literature review, epidemiology, #HTA, #reimbursement policies, etc. ✔️ Analyzing MedTech and Pharma market for dedicated product portfolio and geography ✔️ Regulatory challenges in European and APAC markets ✔️ #KOL Mapping and Expert #interviews ✔️ preparing Business case studies   🔈 Let’s discuss and explore potential #collaboration and mutual benefits. 🔔  For fair business policy, NDA will be signed.   #marketresearch #marketaccess #projectmanagment #jobshadowing #job #hire #hireanexpert #consultation #recruitment

Recent #publication in #healtheconomics!

🔝 The Importance of Responsible and Transparent Communications in Pharma Marketing   ➡️ Citing the article by Marcella Milliet Sciorra, published on Pharmaceutical Executive on January 22nd, 2024, let’s evaluate how effective #corporate #communication plays a crucial role in the context of #pharma market access.   ☑️ Building Trust and Credibility: Clear communication fosters trust between pharmaceutical companies, healthcare professionals (#HCPs), and other stakeholders. When companies transparently share information about their products, #pricing, and #clinical evidence, it enhances credibility and strengthens relationships.   ☑️ Navigating Market Access Challenges: Market access involves demonstrating clinical and #economic evidence, negotiating with payers, and ensuring timely product availability for patients. Effective communication helps address access challenges, ensuring that patients receive the therapies they need.   ☑️ Strategic Choices and Alignment: Companies must formulate clear access objectives aligned with overall commercial goals. Communication ensures cross-functional alignment, clarifies roles, and optimizes processes across functions and affiliates.   ☑️ Early Engagement: Communication should begin early in drug development, incorporating market access perspectives. Engaging a wider set of industry stakeholders and fostering cross-functional collaboration are essential for successful launches.   ➡️ Key message: Pharma #marketing strategies that are both socially and ethically responsible can build long term success for the life sciences industry. #marketaccess #marketingstrategies #corporatecommunication #pharmamarketing